期刊
Molecular Cancer
卷 14, 期 -, 页码 -出版社
BIOMED CENTRAL LTD
DOI: 10.1186/s12943-015-0363-8
关键词
BCR-ABL; Cancer; MRD; CML; SNP; NGS
资金
- Internal Grant Agency of Ministry of Health of the Czech Republic [NT11555]
- Ministry of Health of the Czech Republic [00023736]
- ERDF OPPK [CZ.2.16/3.1.00/28007]
- Czech Leukemia Study Group
- GAUK [554214]
In chronic myeloid leukemia, the identification of individual BCR-ABL1 fusions is required for the development of personalized medicine approach for minimal residual disease monitoring at the DNA level. Next generation sequencing (NGS) of amplicons larger than 1000 bp simplified and accelerated a process of characterization of patient-specific BCR-ABL1 genomic fusions. NGS of large regions upstream and downstream the individual breakpoints in BCR and ABL1 genes, respectively, also provided information about the sequence variants such are single nucleotide polymorphisms.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据